AU2018379644B2 - Prevention and/or treatment of neurodegenerative disease - Google Patents

Prevention and/or treatment of neurodegenerative disease Download PDF

Info

Publication number
AU2018379644B2
AU2018379644B2 AU2018379644A AU2018379644A AU2018379644B2 AU 2018379644 B2 AU2018379644 B2 AU 2018379644B2 AU 2018379644 A AU2018379644 A AU 2018379644A AU 2018379644 A AU2018379644 A AU 2018379644A AU 2018379644 B2 AU2018379644 B2 AU 2018379644B2
Authority
AU
Australia
Prior art keywords
zeaxanthin
composition
administered
medicament
lutein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018379644A
Other languages
English (en)
Other versions
AU2018379644A1 (en
Inventor
Alan Norman Howard
Riona Mulcahy
John Nolan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maravilla LLC
Original Assignee
Maravilla LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maravilla LLC filed Critical Maravilla LLC
Publication of AU2018379644A1 publication Critical patent/AU2018379644A1/en
Assigned to MARAVILLA LLC reassignment MARAVILLA LLC Request for Assignment Assignors: HOWARD FOUNDATION HOLDINGS LTD
Application granted granted Critical
Publication of AU2018379644B2 publication Critical patent/AU2018379644B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018379644A 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease Active AU2018379644B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1720119.5A GB201720119D0 (en) 2017-12-04 2017-12-04 Prevention and/or treatment of neurodegenerative disease
GB1720119.5 2017-12-04
PCT/GB2018/051255 WO2019110951A1 (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease

Publications (2)

Publication Number Publication Date
AU2018379644A1 AU2018379644A1 (en) 2020-03-19
AU2018379644B2 true AU2018379644B2 (en) 2024-02-08

Family

ID=60950313

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018379644A Active AU2018379644B2 (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease

Country Status (15)

Country Link
US (1) US10835509B2 (enExample)
EP (2) EP4599891A3 (enExample)
JP (1) JP2021505527A (enExample)
KR (1) KR20200095452A (enExample)
AU (1) AU2018379644B2 (enExample)
BR (1) BR112020005132A2 (enExample)
CA (1) CA3071786C (enExample)
ES (1) ES3047101T3 (enExample)
GB (2) GB201720119D0 (enExample)
IE (1) IE87241B1 (enExample)
MX (1) MX2020002458A (enExample)
RU (1) RU2020111305A (enExample)
SG (1) SG11202000786RA (enExample)
WO (1) WO2019110951A1 (enExample)
ZA (1) ZA202000558B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3106957B1 (fr) * 2020-02-07 2024-05-03 Abdelhadi Zahouani Composition alimentaire pour stimuler la fonction cognitive et prevenir et limiter le declin cognitif et la demence chez des sujets adultes ou chez des sujets ages denutris
US12076299B2 (en) * 2020-02-20 2024-09-03 Arjuna Natural Pvt Ltd Composition and method to enhance cognitive support and brain health
JPWO2022244727A1 (enExample) * 2021-05-17 2022-11-24
WO2024143060A1 (ja) * 2022-12-26 2024-07-04 サントリーホールディングス株式会社 脳神経細胞保護用組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060166935A1 (en) * 2005-01-24 2006-07-27 Morten Bryhn Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
US20160067203A1 (en) * 2013-07-10 2016-03-10 Lion Corporation Internal composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050163873A1 (en) 2004-01-14 2005-07-28 Robert Ritch Methods and formulations for treating glaucoma
ES2635764T3 (es) * 2007-12-17 2017-10-04 Newtricious B.V. Método de producción de un producto alimenticio funcional basado en yema de huevo y productos obtenibles por el mismo
GB201014340D0 (en) 2010-08-27 2010-10-13 Piraee Mahmood Nutritional supplement formulation comprising saffron and resveratrol
WO2013005037A1 (en) * 2011-07-07 2013-01-10 Howard Foundation Holdings Ltd Improvements in or relating to visual performance and/or macular pigmentation
DE212013000066U1 (de) * 2012-07-19 2014-09-25 U.S. Nutraceuticals Llc Dba Valensa International Krillöl und reagierte Astaxanthinzusammensetzung
GB201300055D0 (en) * 2013-01-03 2013-02-20 Howard Foundation Holdings Ltd Identifying subjects in need of treatment
US20140187648A1 (en) * 2013-01-03 2014-07-03 Howard Foundation Holdings Ltd. Identifying Subjects in Need of Treatment
MX2015013624A (es) * 2013-03-28 2016-06-10 Omniactive Health Technologies Ltd Efecto neuroprotector de carotenoides en el cerebro.
KR20180130501A (ko) * 2016-02-22 2018-12-07 뉴트리셔스 비브이 신경퇴행성 질병의 예방 또는 치료를 위한 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060166935A1 (en) * 2005-01-24 2006-07-27 Morten Bryhn Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
US20160067203A1 (en) * 2013-07-10 2016-03-10 Lion Corporation Internal composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
POWER, R., ET AL., 'SUPPLEMENTAL RETINAL CAROTENOIDS ENHANCE MEMORY IN HEALTHY INDIVIDUALS WITH LOW LEVELS OF MACULAR PIGMENT IN A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL' *

Also Published As

Publication number Publication date
GB201720119D0 (en) 2018-01-17
KR20200095452A (ko) 2020-08-10
ES3047101T3 (en) 2025-12-03
EP4599891A2 (en) 2025-08-13
ZA202000558B (en) 2021-10-27
NZ761512A (en) 2024-01-26
GB2568986A (en) 2019-06-05
IE20180146A1 (en) 2019-06-12
GB2568986B (en) 2019-12-18
RU2020111305A (ru) 2022-01-10
JP2021505527A (ja) 2021-02-18
EP4599891A3 (en) 2025-10-22
GB201807590D0 (en) 2018-06-27
US10835509B2 (en) 2020-11-17
US20190167624A1 (en) 2019-06-06
BR112020005132A2 (pt) 2020-09-15
AU2018379644A1 (en) 2020-03-19
MX2020002458A (es) 2020-07-20
IE87241B1 (en) 2021-07-07
SG11202000786RA (en) 2020-06-29
CA3071786A1 (en) 2019-06-13
EP3644979A1 (en) 2020-05-06
CA3071786C (en) 2023-11-14
EP3644979B1 (en) 2025-08-06
WO2019110951A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
Welty Omega-3 fatty acids and cognitive function
Rautiainen et al. Dietary supplements and disease prevention—a global overview
Otaegui-Arrazola et al. Diet, cognition, and Alzheimer’s disease: food for thought
Berson et al. Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A
Traber et al. Vitamin E revisited: do new data validate benefits for chronic disease prevention?
Bowen et al. Esterification does not impair lutein bioavailability in humans
AU2018379644B2 (en) Prevention and/or treatment of neurodegenerative disease
Demirel et al. The metabolic effects of two different lipid emulsions used in parenterally fed premature infants—a randomized comparative study
Yoshizako et al. Comparison of macular pigment and serum lutein concentration changes between free lutein and lutein esters supplements in Japanese subjects
Scott et al. Pistachio consumption increases Macular Pigment Optical Density in healthy adults: a randomized controlled trial
Tanumihardjo et al. Lutein absorption is facilitated with cosupplementation of ascorbic acid in young adults
US20200197349A1 (en) Cognitive function
Partinen et al. Nutrition, sleep and sleep disorders–relations of some food constituents and sleep
US20190307715A1 (en) Prevention and/or treatment of neurodegenerative disease
Ahmadnia et al. Effect of diet on depression: a review of nutritional solutions
Ulbricht An evidence-based systematic review of lutein by the Natural Standard Research Collaboration
Rodrigues et al. Acute consumption of black walnuts increases fullness and decreases lipid peroxidation in humans
Vishwanathan et al. Increased consumption of dietary cholesterol, lutein, and zeaxanthin as egg yolks does not decrease serum concentrations and lipoprotein distribution of other carotenoids, retinol, and tocopherols
Takeda et al. Effects of mayonnaise on postprandial serum lutein/zeaxanthin and β-carotene concentrations in humans
Summerton Omega-3s: what they can do for you: whether you agree or disagree with the claims, make sure you know the science
EP3672580B1 (en) Composition comprising a xantophyll and an omega- 3 fatty acid and its use for improving cognitive function
Petyaev et al. Pharmacokinetics and oxidation parameters in volunteers supplemented with microencapsulated docosahexaenoic acid
US20140121276A1 (en) Method for alleviating fear memory
Sousa Anti-inflammatory diet and rheumatoid arthritis: overview on the current evidence
Page Macular pigment optical density during pregnancy and its relationship to the diet

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MARAVILLA LLC

Free format text: FORMER APPLICANT(S): HOWARD FOUNDATION HOLDINGS LTD

FGA Letters patent sealed or granted (standard patent)